Media Coverage

ISB Associate Professor Dr. Jennifer Hadlock discussed her recent paper showing that comorbidities play a major role in poor birth outcomes, such as preterm birth and low birth weight, in patients with specific autoimmune diseases.

An ISB-led research project examining autoimmune disease and pregnancy was cited as an example of encouraging critical thinking.

ISB President Dr. Jim Heath talked with Science in Seattle in a wide-ranging interview that touched on his paper in Cell Reports showing how T-cell receptors form, his transition from chemistry to biology, challenges facing life scientists, and more.

As AI and new imaging tools give researchers vast amounts of data on tumors, they are winning some battles against cancer. ISB President Dr. Jim Heath was interviewed for this extensively reported feature story for Newsweek Magazine.

ISB Associate Professor Dr. Sean Gibbons spoke with Mark O. Martin from the University of Puget Sound. Gibbons talked about how the study of host-associated microbial communities gives us insights into evolution, ecology and human health.

ISB and NED Biosystems will collaborate on an intriguing clinical trial that aims to use a cocktail of several marketed medications at low doses to reverse cancer’s onset or regrowth. ISB Co-founder Lee Hood and NED Biosystems founder and CEO Rebecca Lambert announced the deal.

Sean Gibbons was quoted in this Bloomberg Businessweek story examining Viome and the often questionable microbiome-wellness startup space.

This story published by Inside Precision Medicine covers ISB research showing that the different disease-fighting functions of distinct T cells are determined by the genetically encoded T-cell receptor (TCR) sequence that are unique to those cells. The findings are promising for developing custom immune responses to specific antigens.